Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-14T08:57:44.568Z Has data issue: false hasContentIssue false
  • English
  • Français

Efectos diferenciales del milnaciprán, la fluvoxamina y la paroxetina para la depresión, especialmente en el género

Published online by Cambridge University Press:  12 May 2020

Shigeru Morishita  and
Seizaburo Arita
Shigeru Morishita
Affiliation:
“Departamento de Psiquiatría, Facultad de Medicina de Kawasaki, Okayama, Japón
Seizaburo Arita
Affiliation:
Departamento de Matemáticas, Facultad de Medicina de Kansai, Hirakata, Osaka, Japón
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

FluvoxaminaParoxetinaMilnacipránGéneroDepresión
Type
Caso clínico
Information
European Psychiatry (Ed. Española) , Volume 11 , Issue 2 , March 2004 , pp. 124 - 126
Copyright
Copyright © European Psychiatric Association 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Caplea, A, Seachrist, D, Daneshrar, H, Dunphy, G, Ely, D.Noradrenergic content and turnover rate in kidney and heart shows gender and strain differences. J Appl Physiol 2002;92:567–71.CrossRefGoogle ScholarPubMed
Coppen, A, Whybrow, PC, Noguera, R, Maggs, R, Prange, AJ.The comparative antidepressant valué of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatiy 1972;26:234–41.CrossRefGoogle ScholarPubMed
Halbreich, U, Vital-Heme, J, Goldstein, S, Zandek, K.Sex differences in biological factors putatively related to depression. J Affect Disord 1984;7:223–33.CrossRefGoogle ScholarPubMed
Kornstein, SG, Schatzberg, AF, Thase, ME, et al.Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000;157:1445–52.CrossRefGoogle ScholarPubMed
Morishita, S, Arita, S.Possible predictors of response to fluvoxamine for depression. Hum Psychopharmacol Clin Exp 2003;18:197–200.CrossRefGoogle ScholarPubMed
Morishita, S, Arita, S.The clinical use of milnacipran for depression. Eur Psychiatry 2003;18:34–5.CrossRefGoogle ScholarPubMed
Nelson, JCN.Safety and tolerability of the new antidepressants. J Clin Psychiatry 1977;58(Suppl6):26–31.Google Scholar
Old Age Depression Interest Group. How long should the elderly take antidepressant? Br J Psychiatry 1993;162:175–82.Google Scholar
Puech, A, Montgomery, SA, Prost, JF, Prost, JF, Solles, A, Briley, M.Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997;12:99–108.CrossRefGoogle ScholarPubMed
Yonkers, KA, Brawman-Minter, O.The pharmacologic treatment of depression: is gender a critical factor? J Clin Psychiatry 2002;63:610–5.CrossRefGoogle Scholar